CancerDrs

Breast Cancer clinical trials in Maine

8 actively recruiting breast cancer trials at 13 sites across Maine.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Maine:
  • Harold Alfond Center for Cancer Care — Augusta, Maine
  • New England Cancer Specialists - Kennebunk — Kennebunk, Maine
  • Penobscot Bay Medical Center — Rockport, Maine
  • MaineHealth Cancer Care and IV Therapy - South Portland — South Portland, Maine
  • New England Cancer Specialists - Topsham — Topsham, Maine
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Maine:
  • Harold Alfond Center for Cancer Care — Augusta, Maine
  • Lafayette Family Cancer Center-EMMC — Brewer, Maine
  • MaineHealth Cancer Care and IV Therapy - Brunswick — Brunswick, Maine
  • Penobscot Bay Medical Center — Rockport, Maine
  • MaineHealth Cancer Care Center of York County — Sanford, Maine
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…

Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Maine:
  • New England Cancer Specialists — Scarborough, Maine
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Maine:
  • Harold Alfond Center for Cancer Care — Augusta, Maine
  • Lafayette Family Cancer Center-EMMC — Brewer, Maine
  • MaineHealth Maine Medical Center- Scarborough — Scarborough, Maine
  • MaineHealth Cancer Care and IV Therapy - South Portland — South Portland, Maine
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in Maine:
  • New England Cancer Specialists — Scarborough, Maine
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Maine:
  • Harold Alfond Center for Cancer Care — Augusta, Maine
  • MaineHealth Waldo Hospital — Belfast, Maine
  • MaineHealth Maine Medical Center - Biddeford — Biddeford, Maine
  • Lafayette Family Cancer Center-EMMC — Brewer, Maine
  • MaineHealth Cancer Care and IV Therapy - Brunswick — Brunswick, Maine
View on ClinicalTrials.gov →
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Maine:
  • Harold Alfond Center for Cancer Care — Augusta, Maine
  • MaineHealth Waldo Hospital — Belfast, Maine
  • MaineHealth Maine Medical Center - Biddeford — Biddeford, Maine
  • MaineHealth Cancer Care and IV Therapy - Brunswick — Brunswick, Maine
  • Mid Coast Hospital — Brunswick, Maine
View on ClinicalTrials.gov →
Recruiting Industry

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible …

Sponsor: Agendia
NCT ID: NCT03053193
Sites in Maine:
  • Northern Light Breast Care — Portland, Maine
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15